ADC payload and linker selection must be evaluated as one system
ADC linker–payload design is a coupled optimization problem: payload function sets physicochemical and analytical demands, while the linker determines attachment, stability, and the chemical form released. A 2026 review by Samson Gebretnsae describes options ranging from established cytotoxic classes to emerging immune-stimulating, degradation, metabolic, and photoactivated concepts. For R&D teams, the useful output is not a rank order of modalities but a matrix of testable material attributes.
That matrix should connect payload structure, attachment handle, trigger chemistry, spacer and self-immolative units, conjugation distribution, release products, and method capability. Treating any one of these variables in isolation can hide a problem that appears only in the assembled linker–payload or antibody conjugate.
Payload classes create different development questions
The review describes tubulin-directed payloads such as DM1, DM4, MMAE, and eribulin; DNA-reactive agents including calicheamicin and doxorubicin; and topoisomerase I inhibitor payloads such as DXd, SN-38, and exatecan. It also surveys PROTAC payload concepts, immune-stimulating conjugates based on TLR7/8 or STING agonists, NAMPT-inhibitor payloads, and photoactivated systems. These categories identify different molecular functions; they do not by themselves establish the performance of a particular conjugate.
For chemistry teams, the first screen should therefore extend beyond a free-payload potency value. Molecular weight, lipophilicity, ionization, solubility, functional-group compatibility, attachment geometry, and the identity of the released species all affect route design and conjugate characterization. Emerging payload types add assay-specific attributes: degrader concepts require measurement of degradation-related properties, immune agonist concepts require suitable immune-function assays, and photoactive payloads require defined photophysical measurements.
The payload attachment handle is equally important. Its location and reactivity influence protecting-group strategy, late-stage linker installation, impurity formation, and whether conjugation changes the payload’s intended chemical state. A candidate should be evaluated as a defined linker–payload building block, not only as an unconjugated small molecule.
Release triggers should be specified as chemical reaction sequences
The linker families described in the review include non-cleavable designs, acid-sensitive hydrazones, enzyme-cleavable peptides and glucuronides, redox-responsive disulfides, low-oxygen-responsive nitro or azo groups, and light-responsive motifs. Each label is only a starting point. A development specification should name the bond broken, the expected intermediate, any self-immolative step, and the final released species.
- Peptide and self-immolative systems: The review describes VC-PABC designs in which protease cleavage is followed by PABC self-immolation. A GGFG-glycolic acid architecture is described as combining lysosomal proteolysis with acetal hydrolysis. These are multistep release sequences, so intermediates and competing hydrolysis pathways matter.
- Glucuronide-responsive systems: A glucuronic acid unit acts as the enzyme-recognition element, with cleavage initiating self-immolation. Substrate design, spacer electronics, and the stability of the intact glucuronide require separate assessment.
- Redox-responsive systems: Disulfide linkers use a reducing environment to initiate bond cleavage. Substitution around the disulfide can change both stability and reduction rate, making the exact linker structure more informative than the broad “redox-responsive” label.
- Low-oxygen-responsive systems: Nitro and azo motifs are investigated as reductase-sensitive triggers under low-oxygen conditions. The proposed reduction and fragmentation sequence should be confirmed for the actual construct rather than inferred from the trigger class.
- Light-responsive systems: Reported concepts include o-nitrobenzyl motifs. Wavelength compatibility, penetration constraints, photoproduct identity, and energy-transfer requirements need construct-specific verification.
Release studies should distinguish intact conjugate, cleaved linker fragments, transient intermediates, and the intended payload form. Measuring only disappearance of the starting material can miss an incomplete self-immolative step or formation of an unintended product.
Conjugation architecture determines what DAR can and cannot tell you
Drug-to-antibody ratio (DAR) is a distribution, even when it is summarized as an average. Payload hydrophobicity, linker polarity, conjugation site, and attachment chemistry can change that distribution and the associated aggregate profile. A target average DAR is therefore not a transferable design rule across different antibodies or linker–payloads.
Dual-payload ADC concepts raise the dimensionality further. The review describes the need for two orthogonal conjugation chemistries and a bifunctional linker architecture when two payload mechanisms are carried on one antibody. In practice, orthogonality must be tested through reaction selectivity, site occupancy, sequence of operations, and the ability to resolve partially conjugated and cross-reacted species.
The same logic applies to site-specific conjugation. A narrower distribution can simplify one part of characterization, but it does not remove the need to confirm attachment identity, linker integrity, free payload, aggregate content, and release behavior.
Analytical methods should be assigned to specific questions
The review lists hydrophobic interaction chromatography (HIC), reversed-phase HPLC, and LC–MS among methods used for DAR-related analysis, with size-exclusion chromatography (SEC) and analytical ultracentrifugation (AUC) used to examine size or aggregation. These techniques are complementary rather than interchangeable. Their suitability depends on the antibody, conjugation chemistry, payload hydrophobicity, and species that must be resolved.
A practical analytical plan can separate five questions:
- Was the intended linker–payload made? Confirm identity, purity, attachment-handle state, and relevant stereochemical or positional attributes.
- Was it attached as designed? Measure average DAR, distribution, site occupancy where applicable, and residual unconjugated species.
- Is the conjugate physically controlled? Use SEC, AUC, or another suitable orthogonal method to assess aggregate and fragment populations.
- Does the trigger produce the expected chemistry? Track the intact construct, cleavage intermediates, final payload form, and mass balance under defined challenge conditions.
- Can the method see the relevant impurities? Check adsorption, recovery, on-column conversion, ionization bias, and co-elution before interpreting a clean chromatogram as a clean sample.
This question-led approach prevents a method list from becoming a substitute for an analytical control strategy.
A design review should end with testable decisions
Before advancing a linker–payload, an R&D team should be able to state the intended release species, the reaction sequence that generates it, the acceptable conjugation distribution, and the methods that distinguish expected material from plausible impurities. Route scouting should also identify where a trigger, self-immolative spacer, payload functional group, or attachment handle is exposed to incompatible reagents or workup conditions.
The 2026 review provides a broad chemistry map, not universal selection rules. Construct-specific experiments are still needed to set reaction conditions, stability windows, analytical procedures, and acceptance criteria. Keeping those decisions tied to measurable molecular attributes makes comparisons across payload and linker classes more useful without turning reported design concepts into clinical or product claims.
FAQ
What is the role of PABC in a cleavable ADC linker?
PABC is a self-immolative spacer. In a VC-PABC architecture, cleavage of the peptide trigger initiates fragmentation of the PABC unit, connecting enzyme recognition to release of the attached payload form.
What does GGFG mean in ADC linker chemistry?
GGFG is the tetrapeptide sequence Gly-Gly-Phe-Gly. It can serve as a protease-cleavable element in a linker, but the sequence alone does not define stability or release behavior for a complete conjugate.
Which methods can be used to analyze DAR?
The review lists HIC, reversed-phase HPLC, and LC–MS. Method selection depends on what must be resolved, and an average DAR result should be interpreted alongside distribution, site occupancy where relevant, and aggregate measurements.
Does this design framework establish ADC efficacy, safety, or product status?
No. It organizes reported payload classes, linker reactions, conjugation variables, and analytical methods for chemistry development. Efficacy, safety, approval, trial stage, dosing, and product-status conclusions require separate primary or official evidence.
Reference
Gebretnsae S. “Advances in Payload and Linker Designs for ADCs.” AAPS PharmSciTech. 2026;27. https://doi.org/10.1208/s12249-026-03445-z